Medicare Part D plans and drug makers may apply to participate in a new payment model starting in January, which will allow plan sponsors to offer benefits that limit cost sharing for a 30-day supply of insulin to no more than $35. To encourage participation, the model will give qualifying plans that enroll a high number of insulin-dependent patients the option of additional risk corridor protection for calendar years 2021 and 2022. The model also will test how to encourage healthy behaviors and medication adherence through Part D reward and incentive programs. To participate, drug makers may apply through March 18 and Part D sponsors through May 1. CMS plans to make a list of participating drug makers available to Part D sponsors on or around March 20.

Related News Articles

Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Chairperson's File
Public
The recently enacted One Big Beautiful Bill Act will bring big changes to health care. AHA President and CEO Rick Pollack joined me for a Leadership Dialogue…
Headline
The House Ways and Means Subcommittees on Health and Oversight held a joint hearing today to discuss lessons learned, challenges and opportunities to improve…
Headline
The AHA today expressed support for the Medicare Mental Health Inpatient Equity Act, a bill that would eliminate the 190-day lifetime limit on inpatient…
Headline
Rep. Doris Matsui, D-Calif., and Sen. Peter Welch, D-Vt., today introduced the 340B Patients Act, AHA-supported legislation that would codify 340B providers'…
Headline
The AHA July 16 filed an amicus brief in the U.S. District Court for the District of Colorado in defense of the state’s 340B contract pharmacy law prohibiting…